<p>AIM ImmunoTech Inc. has released the latest segment of its CEO Corner, featuring Chief Executive Officer Thomas Equels. In this segment, Equels addresses the significant unmet need in pancreatic cancer and highlights the company’s lead program, Ampligen® (rintatolimod). He discusses Ampligen’s ongoing evaluation in the DURIPANC Phase 1b/2 clinical trial, conducted in combination with AstraZeneca’s Imfinzi® (durvalumab). The CEO Corner segment is now available here (here). Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AIM ImmunoTech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9599761-en) on December 10, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)</p>

<p>AIM ImmunoTech CEO Thomas Equels discusses the progress of Ampligen® in the DURIPANC Phase 1b/2 clinical trial for pancreatic cancer, in combination with AstraZeneca’s Imfinzi®. This update was shared in the latest CEO Corner segment.</p>

AIM ImmunoTech CEO Highlights Ampligen Progress in Pancreatic Cancer Trial